QR код

A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma

Introduction: Immune checkpoint inhibitors (ICIs) have substantially advanced the treatment of patients with malignant melanoma. However, improving therapeutic efficacy requires identifying drug combinations that elicit durable responses without inducing intolerable toxicity. Within that context, se...

Повний опис

Збережено в:
Автори: Mohamed A. Gouda, Bettzy Stephen, Yanyan Tian, Anas Alshawa, Dilichukwu O. Chudy Onwugaje, Aya Albittar, Yali Yang, Abdulrazzak Zarifa, Bulent Yilmaz, Serdar Gurses, Ashabari Sprenger, Mohamed H. Derbala, Amanda Brink, Jeffrey Andrew How, Justin Moyers, Sarina A. Piha-Paul, David S. Hong, Funda Meric-Bernstam, Sapna P. Patel, Isabella Glitza Oliva
Формат: Artigo
Мова:Inglês
Опубліковано: Innovative Healthcare Institute 2024-11-01
Серія:Journal of Immunotherapy and Precision Oncology
Предмети:
selinexor
immune checkpoint inhibitors
melanoma
Онлайн доступ:https://jipo.org/doi/pdf/10.36401/JIPO-24-3
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси